inglês para português Medicina Medicina (geral)

How would you describe your level of familiarity with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)?
Probe: pathology, epidemiology, treatment, etc.
How familiar are you with the fibrotic stages of NASH and their clinical implications, F0 (no fibrosis) – F4 (cirrhosis)?

How familiar are you with the fibrotic stages of NASH and their clinical implications, F0 (no fibrosis) – F4 (cirrhosis)?
How familiar are you with key risk factors for NASH (e.g. obesity, type 2 diabetes)
To your knowledge, how are patients diagnosed with NASH in your market currently?
Probe for unmet needs in diagnosis
How do you expect diagnosis to evolve in the future?

Which attributes will be most important when evaluating access and reimbursement for a new product approved to treat NASH patients?
PROBE: markers of risk for fast progression
PROBE: label population (fibrotic stages)
PROBE: impact of response rates identified in trial/s
PROBE: clinical endpoints, including reducing co-morbidity risks